Is Iron Mountain Stock Outperforming the Dow?
Companies worth $10 billion or more are generally described as 'large-cap stocks,' and IRM perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the REIT - specialty industry.
Trump Is Giving Tesla's Robotaxis a Leg Up Ahead of June 22. Should You Buy TSLA Stock Now?
Dear Nvidia Stock Fans, Mark Your Calendars for July 16
The Trump Family Is Betting Big on Mobile Phones. Should Apple Stock Investors Be Worried?
Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now!
Despite its notable strength, IRM slipped 21.1% from its 52-week high of $130.24, achieved on Oct. 25, 2024. Over the past three months, IRM stock gained 15.3%, outperforming the Dow Jones Industrials Average's ($DOWI) marginal gains during the same time frame.
In the longer term, shares of IRM dipped 2.2% on a YTD basis, underperforming DOWI's YTD marginal losses. However, the stock climbed 16.4% over the past 52 weeks, outperforming DOWI's 9.2% returns over the last year.
To confirm the bearish trend, IRM is trading below its 200-day moving average since late January, with minor fluctuations. However, the stock has been trading above its 50-day moving average since late April.
IRM's strong performance can be attributed to its focus on cash flow in storage and records management, as well as growth in the data center business through strategic acquisitions. The company's expansion strategy includes organic growth efforts and capital recycling to support its growth endeavors. Additionally, IRM's legacy physical storage operations saw stable demand, while its growth businesses grew by over 20%. Overall, the company's results reflect solid performance across all segments, highlighting its successful growth strategy for Project Matterhorn.
On May 1, IRM shares closed up more than 2% after reporting its Q1 results. Its adjusted FFO of $1.17 per share exceeded Wall Street expectations of $1.16 per share. The company's revenue was $1.59 billion, missing Wall Street forecasts of $1.60 billion. IRM expects full-year adjusted FFO in the range of $4.95 to $5.05 per share, and expects revenue in the range of $6.7 billion to $6.9 billion.
In the competitive arena of REIT - specialty, Digital Realty Trust, Inc. (DLR) has taken the lead over IRM, showing resilience with a marginal loss on a YTD basis and 18.2% uptick over the past 52 weeks.
Wall Street analysts are bullish on IRM's prospects. The stock has a consensus 'Strong Buy' rating from the nine analysts covering it, and the mean price target of $115.78 suggests a potential upside of 12.7% from current price levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
23 minutes ago
- The Hill
Australia to reduce US beef import restrictions denounced by Trump as a ban
MELBOURNE, Australia (AP) — Australia will reduce restrictions on U.S. beef imports after U.S. President Donald Trump criticized what he described as an Australian ban on the meat, Agriculture Minister Julie Collins said. Collins said Thursday that relaxing the restrictions designed to keep Australia free of mad cow disease, also known as bovine spongiform encephalopathy or BSE, among its cattle herds would not compromise biosecurity. 'Australia stands for open and free trade — our cattle industry has significantly benefited from this,' Collins said in a statement. Australia has allowed imports of beef grown in the United States since 2019. But Australia has not allowed imports from the U.S. of beef sourced from Canada or Mexico because of the disease risk. But the U.S. has recently introduced additional movement controls that identify and trace all cattle from Mexico and Canada to their farms of origin. US cattle import controls satisfy Australian authorities Australian authorities were 'satisfied the strengthened control measures put in place by the U.S. effectively manage biosecurity risks,' Collins said. The timing of the new, reduced restrictions has not been finalized. Trump attacked Australian import restrictions on U.S. beef when he announced in April that tariffs of at least 10% would be placed on Australian imports, with steel and aluminum facing a 50% tariff. 'Australia bans — and they're wonderful people, and wonderful everything — but they ban American beef,' Trump told reporters then. 'Yet we imported $3 billion of Australian beef from them just last year alone. They won't take any of our beef. They don't want it because they don't want it to affect their farmers and, you know, I don't blame them, but we're doing the same thing right now,' Trump added. Lawmaker fears appeasing Trump endangers Australian cattle industry Opposition lawmaker David Littleproud suspected the government was endangering Australia's cattle industry to appease Trump. 'I want to see the science and it should be predicated on science. I'm suspicious of the speed at which this has been done,' Littleproud told reporters. 'We need to give confidence to the industry, but also to you (the public): this is not just about animal welfare, this is about human welfare, this is about BSE potentially coming into this country and having a human impact, so I think it's important the government's very transparent about the science and I don't think it's even beyond the question to have an independent panel review that science to give confidence to everybody,' he added. Around 70% of Australian beef is exported. Producers fear that export market would vanish overnight if diseases including mad cow or foot-and-mouth disease infected Australian cattle. Will Evans, chief executive of Cattle Australia who represents more than 52,000 grass-fed beef producers across the nation, said he was confident the agriculture department had taken a cautious approach toward U.S. imports. 'The department's undertaken a technical scientific assessment and we have to put faith in them. They've made this assessment themselves. They've said: 'We've looked at this, we've looked at the best science, this is a decision that we feel comfortable with,'' Evans told the Australian Broadcasting Corp. 'When you have a 75 billion (Australian dollar, $50 billion) industry relying on them not making this mistake, I'm sure they've been very cautious in their decision-making,' he added. US beef prices rise because of drought and a domestic cattle shortage Beef prices have been rising in the U.S. due to factors that include drought and shrinking domestic herd numbers. The average price of a pound of ground beef in the U.S. rose to $6.12 in June, up nearly 12% from a year ago, according to U.S. government data. The average price of all uncooked beef steaks rose 8% to $11.49 per pound. Australia's opposition to any U.S. tariffs will be high on the agenda when Prime Minister Anthony Albanese secures his first face-to-face meeting with Trump. Albanese and Trump were to hold a one-on-one meeting on the sidelines of a Group of Seven summit in Canada last month, but the U.S. president left early. Albanese expects the pair will meet this year, although no date has been announced. The two countries have had a bilateral free trade deal for 20 years and the U.S. has maintained a trade surplus with Australia for decades.
Time Business News
24 minutes ago
- Time Business News
Pioneering Advances Reshape the Future of Live Cell Imaging
Live cell imaging is a technique that is used to study living cells in real time, using advanced imaging systems such as fluorescence or confocal microscopy. This allows researchers to inspect cellular processes such as movement, division and interaction without interrupting cells. The market for live cell imaging is increasing due to increasing demand to detect early disease, increase in research in cancer and neurobiology, progress in imaging technologies and more investment in cell-based drug search. Additionally, the growth of personal medical and stem cell research is further enhancing its adoption in both academic and drug fields. Key Growth Drivers and Opportunities Increasing Demand for Detection of Early Disease: The increasing demand for initial disease detection is increasing the increase in live cell imaging market, as this technique enables the real -time view of cellular behavior, which helps researchers to identify abnormalities in early stages. In the progression of the disease, initial insight, especially in cancer, neurodegenerative, and infectious diseases, allow rapid diagnosis and more effective treatment development. It is an accurate, real -time real -time cellular data requiring, which advancing healthcare and research institutes to adopt advanced live cell is imaging systems, promoting market expansion. Challenges Live cell imaging markets face boundaries such as high equipment and maintenance costs, which can restrict adoption between small research laboratories and institutions. Additionally, the complexity of the imaging system requires efficient personnel for operation and data analysis, which is a challenge in resource-limited settings. Live imaging can also affect cell viability over time due to phototoxicity and environmental disturbances, which can affect the result accuracy. Limited standardization and fertility on platforms obstruct the extensive clinical application. Innovation and Expansion An Innovative Live-Cell Imaging System Is Unveiled by a Durham Startup In February 2025, A live-cell imaging system that greatly increases speed and throughput for cell analysis has been introduced by Ramona, a Durham-based supplier of cutting-edge imaging equipment for the life sciences. Ramona wants to raise the bar for throughput speeds and standards using Vireo. Vireo can evaluate a 96-well plate with five channels in less than two minutes, according to the firm. After a year-long early access program for research institutes, the product will be commercially released. The Neuroscience Center and the Carolina Institute for Development Disabilities are two early users at the UNC School of Medicine. For real-time cell analysis, Nanolive introduces the LIVE Cell Death Assay In September 2022, The LIVE Cell Death Assay, a push-button, automated solution for label-free cell health, death, apoptosis, and necrosis profiling, is another revolutionary instrument in the field of cell analysis from Nanolive. First-in-class cytotoxicity analysis of dynamic label-free live cell data is offered by the LIVE Cell Death Assay (LCDA). The LCDA was created with cutting-edge machine learning techniques and has been trained to distinguish between necrosis and apoptosis in addition to living and dead cells. The LCDA is designed to be as easy to use as feasible; all it takes is one button click to begin the analysis. It provides 13 indicators linked to viability and death. Inventive Sparks, Expanding Markets Prominent players working in the live cell imaging market include Thermo Fisher Scientific Inc., Revilit., Nikon Corporation Healthcare, Zes Group and others. Investing in technology innovations involves AI-operated image analysis, super-resolution microscopy, and automation to improve productivity and accuracy, one of the main initiatives for live cell imaging businesses. Business will focus on enhancing your product line by creating affordable and intuitive solutions for a series of research uses, serving both large pharmaceutical firms and small academic laboratories. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
CNBC
24 minutes ago
- CNBC
World's largest olive oil producer warns U.S. consumers of a double whammy from Trump tariffs
Spain's Deoleo, the world's largest olive oil producer, says U.S. President Donald Trump's threat to impose 30% tariffs on imports from the European Union could translate into higher prices for U.S. consumers — as well as limited access to a superfood staple. Trump has threatened to raise tariffs on the 27-member bloc from Aug. 1, in what would mark a steep jump from the current 10% duty. The EU has long been scrambling to reach a trade deal with the U.S. and is considering its options ahead of Trump's deadline, including the prospect of countermeasures. Huge uncertainty persists over whether the U.S. and EU can strike a deal over the coming days, although a blockbuster framework agreement between the U.S. and Japan has raised hopes of a breakthrough. Deoleo, the maker of household olive oil brands such as Bertolli and Carbonell, told CNBC that the Trump administration's trade measures could have an impact on American consumers, particularly given limited U.S. production. "It is worth noting that approximately 95% of the olive oil consumed in the U.S. is imported, so such policies will affect end users," Deoleo CEO Cristóbal Valdés told CNBC by email. The Spanish company said the U.S. accounts for more than a quarter of its total revenue, making it a strategically important market. Around 40,000 acres (16,187 hectares) of olives are planted exclusively in the U.S. for olive oil production, according to the American Olive Oil Producers Association. By comparison, the EU is known to be the leading producer, consumer and exporter of olive oil, with roughly 4 million hectares (9.88 million acres) dedicated to the cultivation of olive trees across the region. Most of the world's supply of olive oil comes from the Mediterranean, with southern European countries such as Spain, Italy and Greece among the world's leading producers of the precious commodity. Spain, in particular, is the biggest olive oil producer in the EU and a global reference for prices. As part of its preparation for a higher tariffs rate, Deoleo's Valdés said the company intends to ramp up its communication, marketing and consumer engagement efforts to ensure olive oil remains an everyday staple. "Beyond institutional dialogue, we are strengthening our value proposition in the U.S. through consumer awareness campaigns about the benefits of olive oil and a renewed commitment to our brands—especially Bertolli, which today represents trust and consistency for American consumers," Valdés said. Deoleo's chief executive also said the olive oil producer would continue to keep all strategic options open, while working on logistics and supply chain improvements to respond to different market scenarios. "However, beyond tactical decisions, our main priority is to protect American consumers' access to a food product that is essential to their health. Access to olive oil should not be penalized — it should be promoted," Valdés said. As U.S. tariffs on EU goods first came into effect in early April, analysts at commodity data firm Expana warned that a reduction in U.S. olive oil imports could have "serious repercussions" for the global market. They cited market players as saying that such a shift could create a supply glut in the EU, leading to further downward price pressure and intensifying competition among producers. It's not just olive oil exporters that have been rattled by Trump's latest tariff threats, however. Irish whiskey firms, Italian cheesemakers and French wine producers are among those who have sounded the alarm over the potential impact.
